Formerly known as Knoll Pharmaceuticals Limited, Abbott India Limited (AIL) is a subsidiary of Abbott Capital India Limited in which the latter holds about 69% stake. It is involved in the discovery, development, manufacture and marketing of pharmace... More
Fresenius Kabi Oncology is the erstwhile Dabur Pharma, which was incorporated in March 2003. The company is a leading player in oncology in India and the international markets. Fresenius Kabi Oncology operates in the regulated markets namely the US a... More
ABBOTT INDIA | FRESENIUS KABI ONCO. | ABBOTT INDIA/ FRESENIUS KABI ONCO. |
|||
---|---|---|---|---|---|
P/E (TTM) | x | 48.3 | 22.1 | 218.2% | View Chart |
P/BV | x | 15.6 | 3.1 | 501.3% | View Chart |
Dividend Yield | % | 0.4 | 0.0 | - |
![]() ![]() |
EQUITY SHARE DATA | |||||
---|---|---|---|---|---|
ABBOTT INDIA Mar-19 |
FRESENIUS KABI ONCO. Mar-13 |
ABBOTT INDIA/ FRESENIUS KABI ONCO. |
5-Yr Chart Click to enlarge
|
||
High | Rs | 8,834 | 176 | 5,019.4% | |
Low | Rs | 5,458 | 79 | 6,952.2% | |
Sales per share (Unadj.) | Rs | 1,731.1 | 37.7 | 4,593.5% | |
Earnings per share (Unadj.) | Rs | 211.9 | 5.1 | 4,160.8% | |
Cash flow per share (Unadj.) | Rs | 219.9 | 6.7 | 3,270.5% | |
Dividends per share (Unadj.) | Rs | 65.00 | 0 | - | |
Dividend yield (eoy) | % | 0.9 | 0 | - | |
Book value per share (Unadj.) | Rs | 945.2 | 42.5 | 2,221.7% | |
Shares outstanding (eoy) | m | 21.25 | 158.23 | 13.4% | |
Bonus/Rights/Conversions | - | - | - | ||
Price / Sales ratio | x | 4.1 | 3.4 | 122.2% | |
Avg P/E ratio | x | 33.7 | 25.0 | 135.0% | |
P/CF ratio (eoy) | x | 32.5 | 18.9 | 171.7% | |
Price / Book Value ratio | x | 7.6 | 3.0 | 252.8% | |
Dividend payout | % | 30.7 | 0 | - | |
Avg Mkt Cap | Rs m | 151,848 | 20,135 | 754.2% | |
No. of employees | `000 | 3.5 | 1.2 | 302.5% | |
Total wages/salary | Rs m | 4,356 | 703 | 619.4% | |
Avg. sales/employee | Rs Th | 10,555.5 | 5,176.2 | 203.9% | |
Avg. wages/employee | Rs Th | 1,249.9 | 610.4 | 204.8% | |
Avg. net profit/employee | Rs Th | 1,292.2 | 699.6 | 184.7% |
INCOME DATA | |||||
---|---|---|---|---|---|
Net Sales | Rs m | 36,786 | 5,963 | 616.9% | |
Other income | Rs m | 1,133 | 18 | 6,293.9% | |
Total revenues | Rs m | 37,919 | 5,981 | 634.0% | |
Gross profit | Rs m | 6,047 | 1,430 | 422.9% | |
Depreciation | Rs m | 169 | 258 | 65.6% | |
Interest | Rs m | 23 | -26 | -86.5% | |
Profit before tax | Rs m | 6,989 | 1,216 | 574.6% | |
Minority Interest | Rs m | 0 | 0 | - | |
Prior Period Items | Rs m | 0 | 0 | - | |
Extraordinary Inc (Exp) | Rs m | 0 | -68 | 0.0% | |
Tax | Rs m | 2,485 | 342 | 726.2% | |
Profit after tax | Rs m | 4,503 | 806 | 558.8% | |
Gross profit margin | % | 16.4 | 24.0 | 68.5% | |
Effective tax rate | % | 35.6 | 28.1 | 126.4% | |
Net profit margin | % | 12.2 | 13.5 | 90.6% |
BALANCE SHEET DATA | |||||
---|---|---|---|---|---|
Current assets | Rs m | 27,610 | 5,102 | 541.2% | |
Current liabilities | Rs m | 8,569 | 2,385 | 359.2% | |
Net working cap to sales | % | 51.8 | 45.6 | 113.6% | |
Current ratio | x | 3.2 | 2.1 | 150.7% | |
Inventory Days | Days | 60 | 150 | 40.1% | |
Debtors Days | Days | 27 | 113 | 24.2% | |
Net fixed assets | Rs m | 1,057 | 5,148 | 20.5% | |
Share capital | Rs m | 213 | 158 | 134.3% | |
"Free" reserves | Rs m | 19,873 | 6,556 | 303.1% | |
Net worth | Rs m | 20,086 | 6,732 | 298.4% | |
Long term debt | Rs m | 0 | 952 | 0.0% | |
Total assets | Rs m | 29,409 | 10,388 | 283.1% | |
Interest coverage | x | 311.6 | -45.8 | -680.7% | |
Debt to equity ratio | x | 0 | 0.1 | 0.0% | |
Sales to assets ratio | x | 1.3 | 0.6 | 217.9% | |
Return on assets | % | 15.4 | 7.5 | 205.0% | |
Return on equity | % | 22.4 | 12.0 | 187.3% | |
Return on capital | % | 34.9 | 14.6 | 239.0% | |
Exports to sales | % | 0 | 74.5 | 0.0% | |
Imports to sales | % | 0 | 24.8 | 0.0% | |
Exports (fob) | Rs m | NA | 4,441 | 0.0% | |
Imports (cif) | Rs m | NA | 1,477 | 0.0% | |
Fx inflow | Rs m | 369 | 5,298 | 7.0% | |
Fx outflow | Rs m | 4,918 | 1,772 | 277.5% | |
Net fx | Rs m | -4,549 | 3,525 | -129.0% |
CASH FLOW | |||||
---|---|---|---|---|---|
From Operations | Rs m | 4,991 | 1,274 | 391.8% | |
From Investments | Rs m | -2,570 | -1,204 | 213.4% | |
From Financial Activity | Rs m | -1,428 | -196 | 728.2% | |
Net Cashflow | Rs m | 993 | -126 | -786.5% |
Indian Promoters | % | 0.0 | 0.0 | - | |
Foreign collaborators | % | 75.0 | 81.0 | 92.6% | |
Indian inst/Mut Fund | % | 7.9 | 0.3 | 2,633.3% | |
FIIs | % | 0.1 | 9.6 | 1.0% | |
ADR/GDR | % | 0.0 | 0.0 | - | |
Free float | % | 17.1 | 9.1 | 187.9% | |
Shareholders | 18,270 | 42,599 | 42.9% | ||
Pledged promoter(s) holding | % | 0.0 | 0.0 | - |
Compare ABBOTT INDIA With: SHASUN PHARMA DR. REDDYS LAB GSK PHARMA ALEMBIC PROCTER & GAMBLE HEALTH
Compare ABBOTT INDIA With: MYLAN (US) ACTAVIS (US) ADCOCK INGRAM (S. Africa) TEVA PHARMA (Israel)
Indian share markets continued their volatile trend during closing hours today and ended their day on a flat note.
For the quarter ended December 2020, ABBOTT INDIA has posted a net profit of Rs 2 bn (down 5.1% YoY). Sales on the other hand came in at Rs 11 bn (up 1.6% YoY). Read on for a complete analysis of ABBOTT INDIA's quarterly results.
For the quarter ended June 2020, ABBOTT INDIA has posted a net profit of Rs 2 bn (up 54.2% YoY). Sales on the other hand came in at Rs 11 bn (up 6.5% YoY). Read on for a complete analysis of ABBOTT INDIA's quarterly results.
For the quarter ended March 2020, ABBOTT INDIA has posted a net profit of Rs 1 bn (down 2.0% YoY). Sales on the other hand came in at Rs 10 bn (up 6.1% YoY). Read on for a complete analysis of ABBOTT INDIA's quarterly results.
For the quarter ended December 2019, ABBOTT INDIA has posted a net profit of Rs 2 bn (up 59.5% YoY). Sales on the other hand came in at Rs 11 bn (up 13.8% YoY). Read on for a complete analysis of ABBOTT INDIA's quarterly results.
For the quarter ended June 2019, ABBOTT INDIA has posted a net profit of Rs 1 bn (up 41.9% YoY). Sales on the other hand came in at Rs 10 bn (up 18.2% YoY). Read on for a complete analysis of ABBOTT INDIA's quarterly results.
More Views on NewsLast time the smallcap index crossed 19k a big correction followed. Here's what makes it different this time.
In this video, I'll show you how to get started on the path to daily trading profits.
An Indian company founded three decades ago in a garage caught my attention...
In this episode of the Investor Hour, India's #1 trader, Vijay Bhambwani, talks to us about the stock market, his new targets for gold and silver, the best long-term investment opportunity, and a lot more.
More